Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 10, 2022 10:02am

196 Views

Post# 35088147

RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

Today's news on pelareorep demonstrating complete responses in pancreatic cancer further confirms that ONCY's acquisition valuation is significantly north of >US$8 Billion as suggested earlier.

November 10, 2022- ONCY Goblet-1 demonstrates complete and partial responses in a cancer with an unmet need that currently lacks any successful treatment options - that will undoubtedly lead the FDA to grant pelareorep + Roche's Tecentriq a speedy "breakthrough therapy" approval that will be fully approved with a confirmatory trial that follows the initial approval of the drug combination.

2022-11-10 09:01 ET - News Release containing findings